A similar negative impact was observed in patients with EGFR‐mutated NSCLC treated with osimertinib or second‐generation EGFR inhibitors, in which ARID1A mutations were observed more frequently in tumors with TP53 alterations [46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.